5-METHYL-3-(3-NITROPYRIDIN-4-YL)CYCLOHEX-2-ENONE, 95.0%, 250mg

4-tert-Butyl-4'-iodobenzophenone, 97.0%, 1g

rel-(3R,4R)-1-(tert-Butoxycarbonyl)-3-hydroxypiperidine-4-carboxylic acid, 98%, 5g

3-Chloro-2,4-difluorophenylacetic acid, 95.0%, 25g

5,6,7,8-Tetrahydro-naphthalene-2-carboxylic acid, 95.0%, 5g

Plan phase PLPHi S40x/0.65 infinity corrected IOS objective. Working distance 0.66 mm

(cyclopentylamino)(oxo)acetic acid, 95.0%, 100mg

Boc-N-methyl-4-chloro-L-phenylalanine, 98.0%, 250mg

PHENYLMETHYLSILOXANE-DIMETHYLSILOXANE COPOLYMER, 500 cSt, 100g

ETALOCIB, 95%, 5mg

4-amino-1H-imidazole-5-carboxamide hydrate, 95%, 25g

3-Indolylacetone, 95.0%, 25g

2-(2-(2-(2-(4-(6-Methyl-1,2,4,5-tetrazin-3-yl)phenoxy)ethoxy)ethoxy)ethoxy)ethanamine hydrochloride, 97%, 100mg